STOCK TITAN

Shareholder of Ocular Therapeutix (NASDAQ: OCUL) files to sell 11,446 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Ocular Therapeutix shareholder Donald D Notman Jr. filed a notice of proposed sale under Rule 144 covering 11,446 shares of common stock. These shares came from restricted stock that vested under a registered plan on 02/11/2026 and are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.

The filing notes that 217,691,779 common shares were outstanding. Over the prior three months, the same seller disposed of 6,035 shares on 02/04/2026 for gross proceeds of 51,540.71 and 5,455 shares on 02/02/2026 for 49,872.88. The signer represents having no undisclosed material adverse information about Ocular Therapeutix.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the OCUL Form 144 filing by Donald D Notman Jr. disclose?

The filing discloses a planned Rule 144 sale of 11,446 OCUL shares. These shares come from restricted stock that vested on 02/11/2026 and are intended to be sold on NASDAQ through Morgan Stanley Smith Barney LLC under Rule 144 resale provisions.

How many Ocular Therapeutix (OCUL) shares has the seller recently sold?

The seller reported two prior OCUL stock sales in the last three months. He sold 6,035 common shares on 02/04/2026 for gross proceeds of 51,540.71 and 5,455 shares on 02/02/2026 for 49,872.88, in addition to the newly planned 11,446-share sale.

What is the source of the 11,446 OCUL shares in the Form 144 filing?

The 11,446 OCUL shares come from restricted stock vesting. The filing states they were acquired on 02/11/2026 through restricted stock vesting under a registered plan from the issuer, with payment described as not applicable, indicating a non-cash equity award vesting.

Which broker will handle the planned OCUL share sale under Rule 144?

The planned OCUL sale will be handled by Morgan Stanley Smith Barney LLC. The broker’s Executive Financial Services office at 1 New York Plaza, 8th Floor, New York, NY 10004 is listed, and the shares are expected to be sold on the NASDAQ exchange.

How many Ocular Therapeutix (OCUL) shares were outstanding in the Form 144 disclosure?

The Form 144 lists 217,691,779 OCUL common shares outstanding. This figure provides context for the relative size of the planned 11,446-share Rule 144 sale and the two earlier sales, which together represent a very small portion of total shares.

What representation does the OCUL Form 144 seller make about company information?

The seller represents having no undisclosed material adverse information about OCUL. By signing the notice, the person states they do not know any material negative information about current or prospective operations that has not already been publicly disclosed.
Ocular Therapeut

NASDAQ:OCUL

OCUL Rankings

OCUL Latest News

OCUL Latest SEC Filings

OCUL Stock Data

1.99B
210.69M
3.33%
90.81%
7.95%
Biotechnology
Pharmaceutical Preparations
Link
United States
BEDFORD